Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

 Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Shots:

  • Janssen enters into an agreement to utilize Iktos’ AI (in silico drug design) technology for the enhancement of speed & efficacy of its small molecules discovery platform and will develop new therapies utilizing Iktos’ know-how in deep generative models applied to chemistry with its own AI expertise
  • Additionally, Iktos has also collaborated with other biopharma companies for its AI technology to expedite the design of compounds and plans to release its SaaS software Makya, a beta version for testing by customers in mid-2019
  • Iktos’ in silico drug design technology improves the drug discovery workflows by utilizing the existing data in designing molecules that are optimized in silico to meet the criteria of a small molecule discovery projects

Click here to read full press release/ article | Ref: Business Wire | Image: Abyss

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post